3
Announcements
Trials
Browse
Landscape
Phase
Phase 1/2
4
Phase 1
3
Phase 2
2
Phase EARLY_PHASE1
1
Phase 3
1
Status
Active not recruiting
15
Recruiting
13
Unknown
5
Completed
3
Terminated
2
Withdrawn
1
Sponsor Class
INDUSTRY
2
Study Type
Interventional
2
Sponsor
Cancer Type
Other hematologic neoplasm
2
Lymphoid
2
Conditions
Precursor T-Cell Lymphoblastic Leukemia-Lymphoma
1
Precursor Cell Lymphoblastic Leukemia-Lymphoma
1
Leukemia, Myeloid, Acute
1
Leukemia
1
Interventions
Cyclophosphamide
166
Docetaxel
154
Bevacizumab
153
Carboplatin
148
Gemcitabine
146
Cisplatin
146
pembrolizumab
144
Radiotherapy
135
Paclitaxel
132
Capecitabine
122
Rituximab
115
Oxaliplatin
104
Fluorouracil
103
Nivolumab
94
Irinotecan
85
Doxorubicin
85
Pemetrexed
83
Leucovorin
82
Dexamethasone
82
fludarabine
74
fludarabine phosphate
72
Bortezomib
69
Etoposide
67
Erlotinib Hydrochloride
66
Cetuximab
65
Methotrexate
58
Trastuzumab
56
Cytarabine
54
Lenalidomide
50
Everolimus
49
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
2 trials
Recent
Start date
Enrollment
Phase 2
×
Terminated
×
isatuximab
×
Clear all
NCT03860844
2025-09-09
ISAKIDS
Sanofi
Phase 2
Terminated
67 enrolled
25 charts
NCT02999633
2022-03-21
ISLAY
Sanofi
Phase 2
Terminated
14 enrolled
7 charts